Matsukawa(T),Yoshida(S),Onozawa(M),Fujii(F... Hematology 2026-12-00

...ELN 2017 adverse-risk, those with TP53 mutations had markedly shorter survival than those with TP53 wild-type (P = 0.018...

Routh(S),Manickam(V) Front Bioinform None

...ELNs was evaluated through DPPH assay and their anti-inflammatory potential was assessed. Further, to elucidate the mole...

Attardi(E),Cipriani(M),Guarnera(L),Savi(A)... Blood Adv 2026-05-26

...ELN) 2022, AML progressing from MDS or MDS/myeloproliferative neoplasm (MPN) (AML post-MDS) mostly clustered in the adve...

Alshemmari(SH),AlSarraf(A),Ameen(R),Alanja... Clin Lymphoma Myeloma Leuk 2026-05-00

...ELN2017, ELN2022 reclassified 14% of patients. Outcomes were effectively discriminated by both ELN2017 (EFS C index 0.60...

Ball(S),Awan(FT),Tomlinson(BK),Stopczynski... Am J Hematol 2026-05-00

...ELN 2022 criteria. Nineteen patients with R/R AML were enrolled. Median age at enrollment was 67.2 (range, 21.1-83.8) ye...

Zhang(L),Ying(S),Fang(F),Li(Q),An(F),Li(J)... Ann Med 2026-12-00

...ELN) risk stratification categorizes acute myeloid leukemia (AML) with myelodysplasia-related gene (MRG) mutations - inc...

Hristovska(I),Pichet Binette(A),Kumar(A),W... Nat Aging 2026-03-00

...ELN, POSTN, CCN2 and especially MMP12, implicating endothelial and smooth muscle cells of the brain. These proteins were...

Wei(ZF),Yan(JQ),Tan(YH),Lin(H),Liu(QJ),Liu... Front Pharmacol None

...ELN) risk category, measurable residual disease (MRD) status, or the number of HiDAC courses. Compared with chemotherapy...

Perrone(S),Corbingi(A),Vetro(C),Palumbo(FE... Ann Hematol 2026-02-12

...ELN) risk stratification, 8 patients were classified as favorable, 20 as intermediate, and 19 as adverse. The median ove...

Nie(X),Li(G),Liu(Z),Ke(B),Yang(Z),Ye(Z),Zh... Int J Gen Med None

...ELNs, as there is no clear standard for ELN retrieval requirements. From an initial cohort of 7001 EGC patients across f...